Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
  • A61B2017/00238—Type of minimally invasive operation
  • A61B2017/00274—Prostate operation, e.g. prostatectomy, turp, bhp treatment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
  • A61B2017/22051—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
  • A61B2017/22065—Functions of balloons
  • A61B2017/22069—Immobilising; Stabilising
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
  • A61B2018/00547—Prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
  • A61B2018/044—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid
  • A61B2018/046—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid in liquid form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F7/12—Devices for heating or cooling internal body cavities
  • A61F7/123—Devices for heating or cooling internal body cavities using a flexible balloon containing the thermal element
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2210/00—Anatomical parts of the body
  • A61M2210/16—Male reproductive, genital organs
  • A61M2210/166—Prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Definitions

• the present invention relates to methods for treating the prostate and/or prostatic urethral stents configured for use after thermal ablation treatments.
• thermal treatment systems have been proposed to treat certain pathologic conditions of the body by heating or thermally ablating targeted tissue.
• These thermal treatment systems have used various heating sources to generate the heat necessary to treat or ablate the targeted tissue.
• laser, microwave, ultrasound, and radio-frequency (RF) energy sources have been proposed to produce the heat that is then directed to the targeted tissue in or around the selected body cavity.
• RF radio-frequency
• thermal ablation system thermally ablates the prostate by a thermocoagulation process.
• This thermal ablation system employs a closed loop liquid or water-induced thermotherapy (WIT) system which heats liquid, typically water, external to the body and then directs the circulating heated water into a treatment catheter which is inserted through the penile meatus and
• WIT water-induced thermotherapy
• the treatment catheter includes an upper end portion which, in operation, is anchored against the bladder neck and an inflatable treatment segment which is held relative to the anchored upper end portion such that it resides along the desired treatment region of the prostate.
• the treatment segment expands, in response to the captured circulating fluid traveling therethrough, to press against the localized or targeted tissue in the prostate to expose the tissue to increased temperatures associated with the circulating liquid, thereby thermally ablating the tissue at the treatment site.
• the pressurized contact can reduce the heat sink effect attributed to blood circulation in the body, thus enhancing the depth penetration of the heat introduced by the inflatable treatment segment into the prostatic tissue.
• BPH benign prostatic hyperplasia
• the circulating hot water is directed through the treatment catheter, which is inserted into the penile meatus up through the penile urethra and into the prostate as described above.
• the treatment segment expands with the hot water held therein to press the inflated treatment segment against the prostate, which then conductively heats and thermally ablates the prostatic tissue.
• the circulating water is typically heated to a temperature of about 60-62°C and the targeted tissue is thermally treated for a period of about 45 minutes to locally kill the tissue proximate the urinary drainage passage in the prostate and thereby enlarge the urinary passage through the prostate.
• the treated tissue in the prostate undergoes a healing process.
• the ablated tissue can expand or swell due to inflammation or edema which can undesirably block or obstruct the prostatic urethra.
• portions of the treated tissue can slough off and create an undesirable and unduly limited opening size.
• a post-treatment catheter such as a conventional Foley catheter, is reinserted and positioned in the subject.
• Foley-type catheters with bladder anchoring balloons located on an upper end portion have been used as post-treatment catheters to allow the thermally ablated tissue to mold around the catheter perimeter during the initial healing phase. While these type catheters allow the post-treatment catheter i to be securely positioned relative to the bladder neck of the subject, natural operation of the sphincter is inhibited, and the configuration is relatively cumbersome (in position it extends through the penile urethra) and can be considered unduly invasive by the user and may increase the risk of urinary tract infection (UTI) when in position in the subject (particularly, when used for extended periods of time).
• UTI urinary tract infection
• prostatic stent that is suitable for use during a post thermal therapeutic treatment (such as ablation) healing process or cycle that can inhibit the closure of the urethra in a manner that reduces abrasion, trauma, or irritation that may be introduced to sensitive tissue along the urethra over conventional treatment procedures.
• the present invention provides, zoter alia, methods for treating the prostate and concurrently forming biocompatible and/or biodegradable stents in the urethra during the same treatment session.
• the stent can be delivered and formed in the prostatic urethra so that it resides above the sphincter, and below the bladder neck, and more particularly, substantially between the bladder neck and the verumontanum.
• the present invention includes methods of treating BPH (and other prostate conditions) in a manner that inhibits obstruction in the prostatic urethra during a healing period after a thermal ablation treatment therapy.
• Certain embodiments of the present invention are directed to methods of treating a condition of the prostate and forming a prostatic stent in situ in the prostatic urethra.
• the method includes: (a) introducing a catheter having an expandable treatment balloon thereon into the male urethra of the subject so that the treatment balloon resides proximate the prostatic urethra; (b) administering a thermal ablation therapy to the prostatic urethra of the subject via the treatment catheter, wherein the thermal ablation therapy has a duration of at least about 10 minutes; (c) releasing biocompatible biodegradeable fluent stent material from the catheter; (d) pressing the fluent stent material into intimate contact with the interior surface of the prostatic urethra by using the expandable treatment balloon; (e) activating the biocompatible stent material in situ to cause it to attach and conform to the interior surface of the prostatic urethra so as to take on a non-fluent form to define a stent having sufficient strength and/
• the pressing step is optional.
• Other embodiments are directed to methods of treating BPH.
• the methods include: (a) thermally ablating localized tissue in the prostate with a treatment catheter having an expandable treatment balloon thereon; (b) flowing fluent viscous or semi-viscous biocompatible and biodegradeable stent material from the treatment catheter into the prostate; (c) molding the flowable stent material to contact the interior surface of the prostatic urethra by expanding the treatment balloon to press the stent material away from the treatment balloon toward the interior surface of the prostatic urethra; (d) securing the stent material to the prostatic urethra so that it defines a resilient conformable stent that remains in position after removal of the treatment catheter to inhibit the closure of the urinary passage; and (e) removing the treatment catheter from the body of the subject.
• the catheter includes: (a) an elongated axially extending shaft; (b) a treatment balloon secured to the shaft and configured to expand outwardly therefrom, the treatment balloon configured to apply a thermal therapy to targeted tissue in the body; (c) a bladder anchoring balloon secured to the shaft above the treatment balloon and configured to expand outwardly from the shaft (that can, in certain embodiments, also substantially securely contact the tissue to define a seal about the upper region above the treatment balloon); (d) a sealing balloon secured to the shaft below the treatment balloon and configured to expand outwardly from the shaft; (e) a urinary drainage channel extending through the shaft; and (f) a flowable biocompatible and biodegradable stent material channel having at least one ejection port formed in the shaft associated therewith, the flowable material channel being in fluid isolation with the drainage channel.
• the shaft is configured and sized such that the portion intermediate the treatment balloon and anchoring balloon has a decreased cross-sectional width relative to the portion of the shaft intermediate the treatment balloon and sealing balloon thereby allowing easy extraction of the catheter after the stent is formed.
• the sealing balloon and the bladder-anchoring balloon are in an expanded configuration when flowable biodegradable stent material is directed to exit the ejection port.
• the catheter can include at least one flushing port and associated flushing channel disposed in the shaft above the at least one dispersing and/or ejection port.
• the flushing port is configured to receive flowable stent material therein and direct it to flow out of the body of the subject in the flushing channel to thereby allow a clinician to verify that the flowable stent material has traveled about the prostatic urethra.
• a sufficient quantity of flowable stent material can be introduced so as to substantially fill the cavity between the treatment balloon and the walls of the prostatic urethra.
• the flushing port may be configured to have a reduced size relative to the ejection/dispersing port to facilitate proper filling of the cavity.
• catheters for treating a condition of the prostate that include (a) an elongated axially extending shaft; (b) a treatment balloon secured to the shaft and configured to expand outwardly therefrom; (c) a bladder anchoring balloon secured to the shaft above the treatment balloon and configured to expand outwardly from the shaft; (d) a urinary drainage channel extending through the shaft; and (f) a non-fluent transformable biodegradeable and biocompatible stent material layer formed over the outer surface of the treatment balloon, whereby when exposed to predetermined temperatures, the stent material is configured to become fluent and released from the treatment balloon to flow to surrounding regions in the prostatic urethra and then, upon exposure to different predetermined temperatures, is configured to become non-fluent and remain in intimate contact with the interior surface of the prostatic urethra to define biocompatible biodegradable stent.
• the shaft is configured and sized such that the portion intermediate the treatment balloon and anchoring balloon has a decreased cross-sectional width relative to the portion of the shaft immediately below the treatment balloon to allow for ease of extraction of the catheter after the stent is formed in situ.
• catheters include: (a) an elongated axially extending shaft; (b) a treatment balloon secured to the shaft and configured to expand outwardly therefrom; (c) an outwardly expandable permeable or porous sleeve configured to overlie the treatment balloon, the sleeve being independently inflatable from the treatment balloon; (d) a quantity of flowable biocompatible biodegradable stent material disposed intermediate the treatment balloon and the sleeve; (e) a bladder anchoring balloon secured to the shaft above the treatment balloon and configured to expand outwardly from the shaft; (f) a sealing balloon secured to the shaft below the treatment balloon and configured to expand outwardly from the shaft; (f) a urinary drainage channel extending through the shaft; and (g) a flowable fluent biocompatible stent material channel having at least one ejection port formed in the shaft in fluid communication with the sleeve so as to direct the flowable biocompatible stent material therein, the flowable material channel being in fluid isolation with the drainage channel.
• Still other embodiments are directed to biodegradable stents for the prostatic urethra.
• the stent is defined by a non-fluent biodegradable biocompatible polymeric material that is in intimate contact with tissue on the surface of the prostatic urethra and extends a distance into a plurality of the acini (prostate ducts), the biodegradable stent having sufficient thickness and length to inhibit closure of the urinary flow passage through the prostatic urethra.
• the stent may be employed post-treatment (to attach to ablated tissue) or for hyperplasia or other prostate or urinary tract conditions.
• Another aspect of the present invention is a set of prostatic treatment catheters, each configured for insertion into the male urethra of a subject as stated above.
• the set is provided such that each is sized a different length to allow customized fit to a particular subject (the portion of the stent body which is adapted to reside in the prostatic urethra itself).
• the present invention provides catheters, methods, and/or post-treatment biocompatible stents that can be delivered via the treatment catheter (before, during, or after active administration of the treatment) in a treatment session so as to inhibit prostate obstruction in the urinary drainage path during post-treatment healing.
• the stents can be made to be biodegradable (that includes bioabsorbable and the like) and configured to reside in the subject above the sphincter during the healing cycle. As the ablated tissue is sloughed off the surface, the stent will be absorbed or discharged from the body.
• the stent will be gradually absorbed and/or flushed out of the subject over about 3 weeks -6 months, hi operation, the stent can be configured so as to have sufficient thickness and resilience to allow drainage and/or flushing liquids to be directed into the subject therethrough even for a patient undergoing increased internal pressures due to edema during a healing period after a thermal ablation therapy has been applied to a localized region of the prostate.
• the instant invention can also reduce irritation introduced to the ablated tissue (which can reduce the number of blood clots produced by the subject) over conventional procedures by eliminating the requirement of inserting a physical conventional mechanical type stent.
• Figure 1A is a schematic illustration of the anatomy of the male urethra showing a treatment catheter and a thermal ablation treatment region in the prostate according to embodiments of the present invention.
• Figure IB is a greatly enlarged partial front view of a treatment catheter according to embodiments of the present invention illustrating the release of flowable biocompatible biodegradeable stent material while in position in the subject.
• Figure 1C is a schematic view of an ablated region of the prostate with a biocompatible biodegradeable stent according to embodiments of the present invention in position in the subject after removal of the treatment catheter so as to be in intimate contact with the ablated tissue.
• Figure 2 A is a sectional view of the prostate illustrating the ablated tissue with the biocompatible biodegradable stent according to embodiments of the present invention secured to the ablated tissue to inhibit closure of the prostatic urethra.
• Figure 2B is a sectional view of the prostate illustrating the ablated tissue with a biocompatible biodegradable stent according to embodiments of the present invention secured to the ablated tissue and in the acini ducts to thereby bolster the structural integrity of the stent.
• Figure 3 is a schematic illustration of a closed loop circulating fluid system according to embodiments of the present invention that is configured to both thermally ablate the targeted tissue and deliver and conform the biocompatible biodegradable stent material to the walls of the prostatic urethra.
• Figure 4 is a block diagram of operations suitable for carrying out embodiments of the present invention. .: ;
• Figure 5A is a perspective view of a treatment catheter according to embodiments of the present invention configured to deliver and apply the biocompatible biodegradable stent to the targeted region in the body.
• Figure 5B is a front view of a treatment catheter according to other embodiments of the present invention.
• Figure 6A is a front view of another treatment catheter according to other embodiments of the present invention configured to provide the biocompatible biodegradable stent.
• Figure 6B is a sectional view of a treatment catheter taken along lines 6B-
• Figure 6C is a sectional view of a treatment catheter taken along lines 6C- 6C of Figure 6A according to embodiments of the present invention.
• Figure 6D is an alternate configuration of the sectional view shown in Figure 6B according to embodiments of the present invention.
• Figure 7 is a partial side section view of a treatment catheter and flowable stent material injection device according to embodiments of the present invention.
• Figure 8 is a front view of a treatment catheter according to embodiments of the present invention in position in the body and contacting and pressing the biocompatible biodegradeable stent material proximate thereto.
• Figures 9A-9D are graphs of the operative temperatures over time for treatment sessions according to embodiments of the present invention using treatment systems to deliver thermal ablation treatments as well as biocompatible biodegradable stents according to embodiments of the activation temperatures.
• Figures 10A-10E illustrate operative configurations of an exemplary treatment catheter according to embodiments of the present invention during use in the subject.
• Figure 11 is a front partial view of a set of treatment catheters according to embodiments of the present invention.
• thermal ablation refers to exposing the targeted tissue to a temperature that is sufficient to kill the tissue.
• the thermal ablation is carried out by exposing the targeted tissue to thermocoagulation via a catheter inserted into the subject which is configured to direct circulating hot liquid that is held captured in the catheter and treatment balloon, and which is heated external of the body of the subject, to the targeted treatment region.
• the targeted tissue is exposed to an elevated temperature that is greater than or equal to about 45°C for a predetermined period of time.
• other treatment types can also be used such as surgical resection or other thermal therapies, particularly those that can generate inflammation in the body.
• the catheters or methods employing biodegradable biocompatible stents according to the present invention may also be appropriate for use in other treated natural lumens or body cavities having intermittent or periodic flow (into, out of, or through) such as the colon, the uterus, the cervix, the throat, the respiratory passages, the ear, the nose, and the like, to inhibit closure or restriction thereof.
• the thermal ablation is directed to treating conditions of the prostate such as cancer and/or BPH.
• the prostatic tissue can be exposed to a temperature that is at or above 50°C-62°C for a treatment period that is typically about 10-60 minutes or longer, and typically between about 20-60 minutes in duration.
• the treatment temperature can be at about 60°C-62°C.
• temperatures of 45°C-50°C may be used. Combinations of different ablation level temperatures with different associated and/or cumulative durations may also be employed.
• the treatment catheter 20 shown in Figure 1 A may be configured to supply the ablation therapy with any desired suitable heating source including RF, microwave, laser, ultrasound, circulating heated fluid, resistive heating, and the like.
• the heat can be directed at the tissue proximate the (expanded) treatment balloon.
• Employing circulating heated fluid may be particularly suitable for administering the thermal ablation procedure and also to activate and form the biocompatible stent 75 in situ.
• thermal ablation therapy be carried out in a localized treatment region within the prostatic urethra, the treatment region 10 being generally described as including the upper portion of the urethra (termed the prostatic urethra) so as to extend generally below the bladder neck and above the verumontanum lib of the subject.
• the treatment region 10 may include the bladder neck or a portion of the bladder neck itself.
• a suitable thermal treatment system is available from ArgoMed, Inc. located in Cary, North Carolina. See also, U.S. Patent Nos. 5,257,977 and 5,549,559 to Eshel, and co-assigned U.S. Patent Application Serial No. 09/433,952 to Eshel et al, the contents of which are hereby incorporated by reference as if recited in full herein.
• the thermal ablation treatment region 10 is indicated by the shaded lined region in the prostate above the sphincter 13.
• an elongated flexible treatment catheter 20 with an outwardly expandable treatment balloon 15 is inserted into the penile meatus along the penile urethra and positioned in the prostatic urethra and secured so that the treatment balloon 15 resides at the desired targeted tissue.
• the treatment catheter 20 includes an axially extending shaft 21 and a urine discharge port 20e that is in fluid communication with a urine discharge or drainage channel 52d that allows urine to drain from the bladder through the catheter 20 while the catheter is in the subject.
• the treatment catheter 20 also includes a bladder anchoring balloon 52, the outwardly expandable treatment balloon 15, and, in certain embodiments, a lower blocking balloon 22.
• the treatment balloon 15 is configured to reside proximate the prostatic urethra above the membranous urethra.
• the lower blocking balloon 22, when used, is configured to reside above the urinary sphincter 13 in the membraneous urethra (and proximate the verumontanum).
• the treatment catheter 20 is also configured to supply and form in situ a biodegradable biocompatible stent 75 (shown as a stent layer 751 in Figure 1 A) that has selective fluent and non-fluent states to the treated region.
• the stent 75 Upon removal of the catheter 20 from the subject, the stent 75 remains in position in a non-fluent state (Figure 1C) and in intimate contact with the prostatic urethra so as to inhibit closure of the prostatic urethra during edema or post-healing inflammation or swelling (as indicated by the lateral inwardly oriented arrows shown in Figure 10E).
• the stent 75 is conformably formed and resiliently configured such that it can follow the contours of the urethra and provide a substantially smooth exposed inner surface while having sufficient rigidity to maintain a sufficiently sized opening in the prostatic urethra treatment region to allow urine drainage during the healing period.
• the stent 75 is configured so as to have good mechanical biocompatibility to sustain a desired opening size 75d ( Figure 2A) but sufficiently compliant so as to reduce the likelihood of introducing injury or shearing the proximate tissue.
• the stent 75 can be formed of a suitable material and thickness 75th as to be able to maintain a desirable opening size in the prostatic urethra lumen when exposed to compressive swelling pressures in the localized treatment region.
• the stent body is able to maintain a sufficient opening size when exposed to compressive pressures from the treated tissue, these pressures may be on the order of about 7-21 psi.
• the stent 75 has a thickness 75th of between about 1-3 mm (on average) along the length of the prostate proximate the location of the treatment balloon 15.
• the stent 75 may provide increased size for the prostatic urethra to discharge urine over the use of conventional Foley type catheters during the first 0-72 hours post- treatment.
• the stent 75 when formed against the urethra walls can be configured to define an inner diameter and corresponding opening width 75d of about 5-25 mm, and typically about 10-20 mm.
• the flowable stent material 75m ( Figure IB) is typically a viscous or semi- viscous fluidic material that can be released from the catheter 20 to be able to disperse, travel or migrate away from the catheter to contact the walls of the prostatic urethra.
• the stent material 75m that forms the stent can be delivered to the prostatic tissue before, during, or after (but proximate in time to) the administration of the thermal ablation therapy.
• the treatment balloon 15 may be used to press, shape, or form the fluent stent material 75m against the wall.
• the flowable stent material can be activated or transformed into the non-fluent state to conform to the inner surface of the prostatic urethra.
• the stent material 75m, stent layer 751 and/or stent 75 can be formed so as to be a good heat conductor.
• good heat conductor means that at ablation temperatures, the temperature drop across the stent or stent material is about 0.5 degrees or less.
• suitable flowable biocompatible biodegradable stent materials that have fluent and non-fluent selectively transformable states are well known and include, but are not limited to, biodegradable biocompatible polymeric materials including polymers and copolymers and mixtures thereof. As used herein, the term
• biodegradable can include bioabsorbable and/or bioerodable or biodischargeable materials that are non-permanent and removed by natural or imposed physiological, biological, chemical or therapeutic processes.
• suitable polymeric materials see U.S. Patent Nos. 4,702,917; 5,634,946; 5, 575,815; 5,674, 287; and 5, 674, 192; the contents of which are hereby incorporated by reference as if recited in full herein.
• the polymeric materials may also include other additives such as plasticizers, medicaments and the like.
• material compositions that include polycaprolactones may be particularly suitable as a bioabsorbable polymer that can be selectively formulated and/or configured for a relatively short degradation process in the body of between about 2 weeks to five or six months, and typically about 2 weeks to about 2 months, by selecting the proper composition, formulation, or formation method (such as by adjusting through copolymerization).
• the polycaprolactone has a crystalline melting point of 60 °C. It is noted that polyanhydrides have been described as suitable for drug matrix delivery and have relatively low glass transition temperatures (such as near body temperature).
• the stent material 75m may comprise medicaments such as therapeutic or symptomatic treatment substances, pharmaceutical agents or drugs, bioactive substances, or food supplements, and the like, used to treat conditions of the prostate (such as BPH) or its symptoms that can be suspended as a matrix in the stent 75 and released in a time matrix format to facilitate the healing process and/or the treatment of the prostate.
• the medicaments can be ejected from the catheter before, during, or after the positioning of the fluent stent material 75m in the .. prostatic urethra either before, after, or during the transformation of the stent material to the non-fluent state. Examples of medicaments will be discussed further below.
• the material 75m can be formulated to be a good thermal conductor to allow for sufficient penetration of heat beyond the stent 75 and into the underlying prostatic tissue.
• the stent material 75m can be selected so that it solidifies or becomes non-fluent at a desired time before, during, or after the thermal ablation treatment so as to not unduly interfere with the thermal ablation treatment, and then remains behind in the body after treatment and removal of the catheter 20.
• the stent material 75m can be delivered to the target site in a fluent or non- fluent state and then subsequently released thereto before, during, or after the thermal ablation therapy in a number of different manners using a treatment catheter.
• the stent material can be configured as a non-fluent outer shell or layer 751 disposed over the outer surface of the treatment balloon 15 on the catheter 20 so that, upon insertion, the stent layer 751 remains on the treatment balloon until a desired release time at which point it is transformed into a fluent state as will be discussed further below.
• the stent material 75m can be introduced into the prostatic urethra so that it is able to travel a distance into the acini (prostate ducts or channels) in the prostate to form anchors or roots 75r (see also Figure 1C) to help secure the stent 75 into the tissue in the body so that it has increased structural reinforcement capability).
• Introducing the stent material 75m with sufficient pressure and/or at a time during the thermal treatment can allow the stent material 75m to migrate into the channels to form roots or anchors 75r.
• an internal massage therapy can be administered concurrently or serially with the thermal ablation therapy (such as by repetitively successively expanding and contracting the treatment balloon) at a time before or during the thermal ablation process.
• the fluent stent material 75m can be directed to exit a permeable or porous sleeve 15s that is positioned over the treatment balloon 15.
• the sleeve 15s can be configured to be concurrently expandable with the treatment balloon as well as independently expandable responsive to the quantity of fluent stent material 75m that is directed to flow from the sleeve inlet port 16p and associated flow channel 16c.
• the sleeve 15 may be configured as a low thermal resistance elastic sleeve that helps the catheter maintain a low profile upon insertion and removal to force the treatment balloon tightly against the surface of the shaft, even after exposure to ablation level temperatures.
• the sleeve 15s is elastic and can be formed from an elastomeric material having a Shore A (Type A) durometer range of between about 20 and about 60.
• the thickness of the elastic sleeve 15s can, in certain embodiments, be between about 0.005 inches and about 0.030 inches (about 0.127-0.762 mm).
• the sleeve 15s should be configured so as to not substantially interfere with the heat transfer from the underlying treatment balloon 15 during the thermal ablation treatment.
• Elastomeric materials that may be suitable to form the sleeve 15s include, but are not limited to, silicone, natural rubber, synthetic rubber, and plasticized polyvinylchloride (PVC).
• PVC plasticized polyvinylchloride
• the permeable or porous sleeve 15s may be used in combination with the dispersing and/or flushing ports and channels as desired.
• the sleeve 15s may also be formed of biodegradable materials.
• the sleeve 15s (or a portion thereof) may be configured such that it is absorbed into the body over time or so that it dissolves after it enters the body at some point in time before, during, or after the treatment.
• the sleeve 15s may be used to form the stent 75.
• suitable biodegradable materials include polymers, copolymers and polymer compositions. Exemplary biocompatible biodegradable absorbable materials were described above and others are described in U.S.Pat. Nos.
• fluent stent material 75m is flowably directed up in the catheter via one or more flow channels so that it travels through the catheter 20 to be released from one or more injection or dispersing apertures 80 formed in the outer wall of the catheter 20 about the treatment region.
• the at least one dispersing aperture 80 may be positioned in the shaft 21 above and/or below the treatment balloon 15 and includes an associated material flow channel 80c ( Figures 5A, 6B).
• a plurality of spatially separated dispersing apertures 80 may be used, each in fluid communication with a common or individual flow channel.
• At least one (or a plurality of radially spaced) dispersing apertures 80 can be positioned both above and below the treatment balloon 15 so that a sufficient quantity of fluent stent material 75m can be distributed and/or sprayed about the prostatic urethra as shown in Figure IOC.
• one or more dispersing or injection apertures 80 may be positioned below the treatment balloon 15 and one or more flushing apertures 85, each having a common, shared, or separate associated flushing channel, can be located above the treatment balloon 15.
• the treatment balloon 15 may be partially or wholly deflated when the stent material 75m is ejected from the dispersing ports 80.
• the stent material 75m can be forcibly ejected from the dispersing ports 80 under pressure such that the stent material 75m rises to the location proximate the flushing port 85.
• the flushing port 85 may be sized and configured to be smaller than the dispersing port 80 so as to impede or reduce the amount of stent material 75m that flows therein (thereby keeping a substantial or major portion of the material 75m in the prostatic urethra), hi particular embodiments, the flushing port 85 may be from about 10-75% smaller in width than the dispersing port 80. In operation, a quantity of stent material 75m will then enter the flushing port 85 and travel through the associated flushing channel 85c ( Figures 5A, 6C) to exit the catheter 20.
• a clinician can monitor the external orifice of the flushing channel 85c to determine when/if sufficient quantity of fluent stent material 75m has been distributed and/or circulated or delivered in vivo based on the confirmation that a suitable quantity has exited the catheter via the flushing channel(s) 85c (that is in fluid isolation from the flow channel (s) 80c).
• the external orifice of the channel (such as via flexible tubing 18t) associated with the flushing port 85 can be closed or blocked off (with a valve means or plug) 85p after sufficient quantity has exited the catheter to terminate excess leakage of .
• stent material 75m from the body as shown in Figure 3.
• the treatment catheter 20 may also include a lower sealing balloon 22.
• the sealing balloon 22 Prior to releasing the stent material 75m in fluent form from the catheter, the sealing balloon 22 can be expanded to contact the walls of the membraneous urethra to substantially seal the urethra above the sphincter. In this manner, the stent material 75m is inhibited from flowing below the sealing balloon 22.
• the sealing balloon 22 can be concu ⁇ ently inflatable with the treatment balloon 15 (in fluid communication therewith) or separately inflatable having its own inflation channel, inflation port and source.
• the sealing balloon 22 can be configured to take on a shape that can be described as a pear shape, ramped or inclined shape, or frusto-conical shape, when expanded. This allows the profile of the sealing balloon 22 to taper out from the top to the bottom, thereby inhibiting movement of the catheter 20 toward the sphincter 13 when the sphincter 13 relaxes or opens.
• this shape may also inhibit upward movement of the catheter body toward the bladder, as the upper portion of the prostatic Urethra, especially when the treated tissue is swollen, inflamed or suffering from edema, tends to close down or restrict the opening area in this region.
• the sealing balloon 22 which can be positioned in the in the membranous urethra, will abut the restricted opening size of the urethral canal thereabove, in the treatment region, thereby inhibiting upward movement or migration of the catheter 20.
• the present invention is not limited thereto and other balloon shapes may also be employed, as may co ⁇ esponding elastic sleeves with various shapes and configurations including, but not limited to, pear shapes, ramped or inclined shapes, bulbous shapes, elliptical shapes, oval shapes, cylindrical shapes, accordion pleated shapes, shapes with tapered fins (such as circumferentially disposed about the perimeter of the lower portion of the stent body), and the like.
• the anchoring balloon 52 may be configured in any suitable shape.
• the fluent material 75m can be pressed against the wall or interior surface of the prostatic urethra by the expansion of the treatment balloon 15 and then transformed into a non-fluent state by exposing the stent material 75m to an activation mechanism or reaction source such as chemical (polymerization or cross-linking), electrical, or mechanical, including, but not limited to, heating, cooling, or exposing the fluent material 75m to light in situ.
• an activation mechanism or reaction source such as chemical (polymerization or cross-linking), electrical, or mechanical, including, but not limited to, heating, cooling, or exposing the fluent material 75m to light in situ.
• two different fluent materials or material mixtures can be directed to travel through the catheter in fluid isolation and ejected from the catheter separately under pressure so that they mix in situ to react to transform the combined mixture into the biocompatible biodegradable non-fluent stent.
• One of the materials or material mixtures may be directed to exit the catheter through the porous or permeable sleeve 15s, or each may have its own ejection channel and port.
• the lower portion of the shaft 211 of the catheter can include elongated channels 21c that can function as fluid flow channels (such as channels 80c and/or 85c that are in fluid communication with injecting/dispersing aperture 80 and flushing aperture 85, respectively) and/or can provide increased shaft insulation 21i that encases one or more internal fluid lumens 21c (such as the drainage channel 52d, and/or inlet and outlet circulating fluid channels 26i, 26o or other desired flow paths) as desired for particular embodiments of the invention.
• the increased insulation 21 i can include a number of axially extending channels that encase the inner lumens. See co- assigned concurrently filed U.S. Application Serial No.
• FIG. 6A illustrates another embodiment of a catheter 20 that can be configured to be conformable to the contours of the urethra upon insertion and includes a plurality of elongated channels 21c that define increased insulation 21 i for a lower portion of the shaft 21.
• Figures 6B and 6D illustrate different elongated outer and inner channel configurations (and/or wall structures). As shown, one of these channels 21c is the fluid material flow channel 80c.
• channels 21c can be used to inflate the anchoring balloon 52 and the sealing balloon 22 (and may also be used to supply the sleeve with fluid material or to direct medicaments to the treatment region where desired).
• the elongated channels 21c encase internal fluid lumens such as the drainage channel 52d and the inlet and outlet fluid circulating channels 26i, 26o, respectively.
• Figure 6C illustrates a different view taken about the flushing port. As shown, one of the elongated channels 21c, is in fluid communication with the flushing port 85 and provides the associated flushing channel 85c.
• Figure 8 illustrates the treatment catheter 20 in position in the subject with the stent material 75m released therefrom and positioned about the prostatic urethra. As shown, the stent material 75m extends an axial length that co ⁇ esponds to the distance between the lower portion of the anchoring balloon 52 and the upper portion of the sealing balloon 22.
• Figure 7 illustrates that a syringe 96 with a quantity of stent material 75m that may be used to engage with the desired flow channel(s) in the catheter to deliver the stent material to the dispersing port(s) 80 (and/or to flow channel 16c then to sleeve port 16p) under pressure.
• An exemplary quantity of stent material 75m that may be deployed to form the suitable stent thickness and size includes, but is not limited to, at least about 20 ml- 100 ml.
• the syringe 96 may be manually operated or automatically operated such as via a stepper motor 96m that automatically translates the plunger 96p of the syringe 96 to inject the stent material under pressure.
• a pressure sensor (not shown) may be employed to allow a controlled pressure release as desired.
• Figures 9A-9D illustrate examples of temperature cycles over a treatment session that can be used to administer a thermal ablation therapy and to transform the stent material 75m to its desired fluent and or non-fluent forms during, before, or after the thermal ablation therapy.
• Figure 9A illustrates that the stent material can be released or placed into the prostate before the thermal therapy and the thermal ablation therapy can be administered at a substantially constant temperature of between about 50-60°C (for a time "Tl").
• Tl time
• the ablation energy travels through the stent 75 such that it either becomes non-fluent early in the ablation treatment session or becomes non-fluent when the temperature is ramped down to body temperature at the end of the treatment session.
• Figure 9B illustrates that the treatment can be ca ⁇ ied out a first ablation temperature threshold for a major portion of the therapeutic treatment (“Tl”) and then elevated to a second increased temperature toward the end of the treatment session ("T2).
• the stent material 75m may be located in the body prior to the initiation of the treatment (such as an outer layer on the treatment balloon 15) but the stent 75 does not become non-fluent until after the time designated as "Tl" when it reaches its activation threshold.
• Figure 9C illustrates that the ablation therapy can be carried out and then the stent material 75m cooled at time T2 to cause it to become non-fluent.
• the stent material can be introduced between times Tl and T2 or during or before Tl .
• Figure 9D illustrates that the thermal ablation therapy can be carried out at a first threshold level similar to Figure 9B, and after the thermal therapy is completed, the thermal source is interrupted to insert the flowable material into the prostatic urethra. Then an activation thermal cycle can be commenced during time and a second selected temperature "T2" to transform the stent material 75m to its non-fluent form. Alternatively, a major portion of the thermal treatment can be administered (that may be represented by the time "Tl”) and then interrupted for a brief period to insert the material 75m and then completed at a different temperature level during time T2.
• treatment temperature cycles and timing may also be used according to the ablation temperatures desired, depth of penetration desired, and stent material and composition and configuration employed as will be appreciated by those of skill in the art.
• a portion of the shaft 21b that portion that extends below the treatment balloon 15, can be configured to have a diameter or width that is greater than the portion of the catheter shaft 21a that is above the treatment balloon (the portion intermediate the treatment balloon 15 and the anchoring balloon 52).
• the larger shaft 21b can be sized so as to accommodate the dimension of the anchoring balloon 52 and treatment balloon 15 over its shaft (when deflated). As such, the increased size portion of the shaft 21b may be about 5-25% larger than the (upper) reduced size portion 21a.
• certain portions of the catheter 20 such as the bottom portion of the catheter 20b that resides above the sphincter 13 can be configured to have radio-opaque indicia 77 (as denoted by the shaded region along the upper portion of the catheter.
• the indicia 77 can be any suitable radio-opaque feature such as a marker, surface, layer, or other feature so as to be imageable or visualized in an X-ray (to allow external positional verification of the device).
• Figure 5A illustrates that a series of radio-opaque markers may be employed, some axially extending and some radially extending to help confirm the positional location of the catheter when in the subject, i ⁇ espective of its orientation in the body.
• the stent material may also be configured to be externally detectable (such as with a radio-opaque dye or other additive/composition) so as to allow external positional verification by X-ray or other desired means.
• X-rays can be taken at insertion/placement (initial positioning) and can also be taken periodically during to confirm proper positioning in the subject in situ.
• the radio-opaque markers 77 can be circumferentially a ⁇ anged on the catheter either or both above 77u and below 771 (see also Figure 1 A) the sealing balloon 22 so that the balloon 22 can be more readily accentuated and confirmed in the X-ray as located in the membranous urethra, above the sphincter.
• one or more longitudinally extending radiopaque markers 77a can be a ⁇ anged to extend substantially along the length of the treatment balloon 15 at various radial positions (preferably at least 4 positions symmetrically separated and aligned about the cross-sectional width of the catheter, typically at 90 degree radial separation to allow for X-ray identification i ⁇ espective of the image angle).
• the radio-opaque markers are applied to block the transmission of X-ray for better contrast in images.
• the opacity, degree of contrast, and sharpness of the image may vary with material and type of process used to create the marker.
• the radio- opaque marker(s) may be a ⁇ anged on the catheter by any suitable biocompatible marker, such as non-toxic radiopaque coatings, inks, thin-films, paints, tapes, strips, shrink tubing, and the like. See e.g., Richard Sahagian, Critical Insight: Marking Devices with Radiopaque Coatings, Medical Device & Diagnostic Industry (May, 1999), also available at URL deviceline.com/mddi/archive/99/01/011.html.
• radiopaque markers include polyolefin inks available as No-Tox® Medical Device Polyolefin Inks from Colorcon, and resin compounds with barium sulfate and/or bismuth such as is available from New England Urethane fric. of North Haven, CT. See also Danilychev et al., Improving Adhesion Characteristics of Wire Insulation Surfaces,
• medication, drugs, treatments, rinses, and the like can be introduced into the subject through an external medication port inlet and associated channel.
• the channel can be the urinary drainage channel 52d or other of the elongated channels 21c in the catheter or can be formed as its own separate channel and release port (not shown).
• the fluid (or mixture) can be directed to exit a desired port after the fluid travels through the catheter to the treatment site or proximate the treatment site.
• the medication inlet port can be provided with any suitable valve/port device as is known to those of skill in the art. Suitable valve devices (for both the inflation system and the medication delivery system) are available from medical device manufacturers such as Alaris Medical Systems (SmartSite® system) and B.
• the treatment balloon 15 may be provided in several lengths from about 3-12 cm, and typically from about 1-6 cm.
• the catheters 20 may be provided as a set with a range of lengths (such as in 0.5 cm increments) so as to allow a clinician to select from an easy compliment of assorted sizes and thus readily employ the size that fits the patient.
• the catheters may be provided as a kit or set of catheters as shown in Figure 11 with various lengths of treatment balloons 15 with the ports 80, 85 positioned at opposing ends of the treatment balloon (above and below) thereon.
• the outer surface of the catheter 20 can be configured with a biocompatible lubricant or low-friction material to help reduce discomfort associated with the insertion of the catheter device into the body as well as to promote the separation of the treatment balloon from the stent material 75m in the body.
• Coatings that may be appropriate include coatings that promote lubricity, and wettability.
• a hydrophilic coating which is applied as a thin (on the order of about 0.5-50 microns thick) layer which is chemically bonded with UN light over the external surface of the stent 20.
• Hydrolene® available from SurModics, Inc., of Eden Prairie, M ⁇ .
• Other similar products are also available from the same source.
• the catheter 20 can be configured not only to provide the lubricious coating but to also include bioactive ingredients configured to provide sustained release of antibiotics, antimicrobial, and anti- restenosis agents, identified as LubrilLastTM from AST as noted above.
• bioactive ingredients configured to provide sustained release of antibiotics, antimicrobial, and anti- restenosis agents, identified as LubrilLastTM from AST as noted above.
• One suitable material may be the antimicrobial silver zeolite based product available from HealthShield Technologies LLC of Wakefield, MA.
• Another alternative is a Photolink® Infection Resistance antimicrobial coating or a hemocompatible coating from SurModics, Inc. of Eden Prairie, M ⁇ .
• the coating may also include other bioactive ingredients (with or without the antimicrobial coating), such as antibiotics, and the like.
• LubriLASTTM lubricious coatings from AST of Billerica, MA.
• the flow channel 80c, dispersing port 80, and/or flushing channel and port 85c, 85 can also be used to collect fluid specimens from the prostate region during the treatment (via gravity feed or suction and the like). Typically, the specimen is obtained prior to releasing the stent material into the prostatic urethra cavity.
• These types of internal prostatic fluid specimens may be collected in a manner that is representative of its condition in the body (substantially void of urine and the like) to allow for a better specimen for analysis. See co-pending and co-assigned U.S. Provisional Patent Application Serial No. 60/330,029.
• closed end configurations of the catheter 20 shown herein have been illustrated as substantially upright, they can also be curved into other configurations such as Coude or Tiemen.
• Medicaments that may be incorporated into the stent 75 (such as in a slow release matrix formulation) and or delivered separately include, but are not limited to, analgesics, anti-depressants, phytotherapy therapeutics such as PEENUTS or PROSTA-Q, anti-inflammatory agents such as steroid inhibitors (such as COX-2 inhibitors like NIOXX) and PE ⁇ TOSA ⁇ POLYSULFATE, non-steroid inhibitors, antibiotics, neuroleptic agents (such as ELNAIL, ⁇ EURO ⁇ TI ⁇ , DOXEPI ⁇ , and MARCAI ⁇ E), ⁇ -blockers (such as PHE ⁇ OXIBE ⁇ ZAMI ⁇ E), specific immunology modulators such as E ⁇ BREL (by Immunex, a drug approved by the FDA for rheumatoid arthritis), bioflavinoids to reduce the level or oxidants in the prostatic fluid, FI ⁇ ASTERIDE, TERAZOSI ⁇ , ALFUZOSI ⁇ , antioxidants, quercitan, and the like,
• Figure 3 illustrates one embodiment of a thermal treatment system 100 that can be configured as a closed loop circulating fluid system.
• the closed loop system 100 can be configured as a low-volume system to circulate between about 20-100 ml at any one time through the system (including the catheter 20 and the tubing 26t).
• the system 100 includes a fluid circulation pump 160, a pressure monitoring and controlling device 150, a heater 140, temperature sensors 106, and a controller 120.
• the system 100 can be configured with a patient interface device 120u to allow a patient to adjust the treatment pressure.
• the arrows in the figure illustrate the direction of the circulating fluid flow in the system and catheter.
• the stent material flow channel 80c can also be used to obtain a prostatic fluid specimen from the prostate.
• the syringe 96 may be replaced with a pump or length of conduit that connects to the existing circulation pump 160 to draw or direct the fluid therein to discharge downstream of the pump 160 into a biosample collection chamber or container to provide the suction force to obtain the prostatic fluid biosample.
• gravity, capillary action, or other collecting means may be . employed. See e.g., U.S. Patent Application 09/433,952 and U.S. Patent 5,549,559, the contents of which are hereby incorporated by reference as if recited in full herein, for descriptions of a suitable closed loop circulating fluid system.
• Fluid circulating WIT catheters with expandable treatment balloons are available from ArgoMed, Inc., in Cary, NC.
• the pressure in the treatment balloon (which co ⁇ esponds to the pressure in the closed loop system) may be from about 0.5-4 atm, and typically at least about 0.75-2 atm during at least a portion of the treatment to increase the force (that may be pulsatile) presented to the localized tissue. ...
• the circulation can be provided by using a peristaltic pump to generate pulsatile fluid flow.
• a three-roller pump may be configured to operate to provide about 1-12 or 1-20 expansion and contraction pulses per second to about 1-12 or 1-20 pulses per minute in the balloon.
• this action can be caused by using a pulsatile flow pump having three rollers with between about 200-750 rotations per minute while a two roller pump may be configured to operate with between about 200-500 rotations per minute; each can operate so as to provide a co ⁇ esponding number of pulses to the treatment balloon.
• Suitable pump heads are available from Watson Marlow
• a treatment catheter is position in the subject so that a treatment balloon resides proximate the prostatic tissue (block 200) and administers a thermal ablation treatment (block 205).
• Flowable stent material that is selectively transformable from fluent to non-fluent states is released from the thermal ablation treatment catheter in a fluent state to reside about the prostatic urethra (block 210).
• the flowable stent material can be a viscous or semi- viscous material in the fluent state.
• the fluent stent material can be formed or pressed against the prostatic urethra wall or inner surface by expanding the treatment balloon (block 220).
• the stent material is activated in situ to cure or become non-fluent and form the stent in the body (block 230).
• the stent material can be activated via heat (block 222), cooling (block 223), exposure to light (ultraviolet, etc) (block 224), or by chemical reaction (block 225).
• the treatment catheter is removed from the subject leaving the stent in the treatment region (block 240).
• the flowable stent material can be introduced before, after, or during the administration of the thermal ablation therapy and then activated in situ to form a resilient biodegradable biocompatible stent that inhibits obstruction of the urethra during post-treatment healing (block 212).
• the flowable stent material can be configured to be applied via a non-fluent coating or layer applied to the outer surface of the treatment balloon that becomes fluent in the body when heated and then transforms back to its non-fluent state upon cooling to remain (block 14a).
• the stent material can be held in the catheter in a fluent state and dispersed from the treatment catheter in a fluent state (block 214b).
• the catheter can be configured to circulate heated liquid in a closed loop system through the prostate.
• the circulating heated liquid is directed through the catheter to a treatment balloon such that it travels, captured in the catheter, through the penile meatus, along the penile urethra the bulbous urethra, and the membranous urethra to a localized treatment region in the prostate inside the treatment balloon.
• the tissue in the localized treatment region in the prostate is exposed to a temperature above about 45°C for a predetermined thermal ablation treatment period by exposure to contact with the expanded balloon that contains the heated circulating liquid (typically at about 50-62°C for more than about 20-60 minutes).
• the localized treatment region can be an upper portion of the urethra (typically called the prostatic urethra), leaving the lower part of the urethra (the membranous urethra), non-ablated.
• the liquid does not directly contact the tissue.
• This can be accomplished in closed loop circulating systems, which heat the liquid remotely, by insulating the shaft of the treatment catheter up to the treatment balloon to inhibit the exposure of non-targeted tissue to ablation temperatures.
• the circulating fluid can be heated to lower treatment temperatures, such as between 45-50°C, or even less than 45°C (such as
• FIG 10A illustrates the treatment catheter 20 in position and administering a thermal therapy (such as a thermal ablation therapy) to the subject (the heat dispersion is shown by the lines with arrows in the prostate in the figure).
• a thermal therapy such as a thermal ablation therapy
• the sealing balloon 22 can be deflated.
• Figure 10B illustrates the release of fluent stent material 75m from the catheter and its movement upward away from the dispersing port(s) 80 to the flushing port(s) 85.
• the sealing balloon 22 is inflated to contact and substantially seal against the membraneous urethra to contain the material above the sphincter 13.
• the treatment balloon 15 may be partially or wholly deflated during this operation to allow the stent material to flow upwardly with less restriction.
• the stent material 75m can be introduced in sufficient quantity to substantially fill the prostatic cavity between the balloons 52 and 22 and the treatment balloon 15.
• Figure IOC illustrates an alternative configuration, whereby stent material 75m (shown by the dark lines with a ⁇ ows) is released from dispersing ports located both above and below the treatment balloon 15 (that may be partially or wholly deflated).
• the sealing balloon 22 can be configured to expand a greater distance than the treatment balloon 15 (indicated by the width, "LW").
• Figure 10D shows that the treatment balloon 15 can be expanded to press and/or form the fluent stent material 75m to the walls of the prostatic urethra and to apply heat to activate or transform the stent material so as to make it non-fluent.
• Figure 10E illustrates that to remove the catheter 20, all balloons 52, 25, 22, are deflated, and the stent 75 remains in position and inhibits the closure of the prostatic urethra during post-treatment inflammation (shown by the converging a ⁇ ows directed at the urethra passage).
• Figure 10D may also be referenced to illustrate another embodiment where the stent material 75m can be released from the treatment balloon 15 to radially disperse about the length of the treatment balloon 15.
• the stent material 75m can be released through a porous or permeable sleeve 15s.
• the stent material 75m can be configured as a nonfluent outer layer 751 formed over the treatment balloon 15 ( Figure 1A) as discussed above.
• Figure 10D also illustrates the treatment balloon 15 can be expanded during this release as desired.
• the biocompatible biodegradeable stents of the present invention can fuse with the urethral tissue.
• This bio-attachment can decrease the potential that the stent will dislocate from its intended location during the healing period and may be particularly suitable for treating conditions of the prostate having increased internal pressures such as inflammation of the prostate (such as is associated with post- ablation procedures and the like) and/or hyperplasia.
• the methods and catheters of the present invention may be used for other applications, such as to treat and/or form biodegradable stents and the like for other natural lumens or body cavities that have periodic fluid or solid movement of biomaterials therethrough, such as the rectum, the colon, the cervix and/or uterus, the bladder, the throat, the ear, the nose, passages of the heart and/or associated valves, portions of the respiratory system, the esophagus, the stomach, bile ducts, and the like.
• biomaterials such as the rectum, the colon, the cervix and/or uterus, the bladder, the throat, the ear, the nose, passages of the heart and/or associated valves, portions of the respiratory system, the esophagus, the stomach, bile ducts, and the like.

Landscapes

• Health & Medical Sciences (AREA)
• Surgery (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medical Informatics (AREA)
• General Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Plasma & Fusion (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Physics & Mathematics (AREA)
• Molecular Biology (AREA)
• Animal Behavior & Ethology (AREA)
• Otolaryngology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Thermotherapy And Cooling Therapy Devices (AREA)
• Media Introduction/Drainage Providing Device (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)
• Prostheses (AREA)
• Materials For Medical Uses (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22937707

Family Applications (2)

Family Applications After (1)

Country Status (4)

Cited By (28)

Families Citing this family (221)

Citations (4)

Family Cites Families (52)

• 2001
  • 2001-11-13 JP JP2002558914A patent/JP2004529676A/ja not_active Withdrawn
  • 2001-11-13 WO PCT/US2001/047789 patent/WO2002058577A1/en not_active Ceased
  • 2001-11-13 WO PCT/US2001/047793 patent/WO2002058578A1/en not_active Ceased
  • 2001-11-13 DE DE10196865T patent/DE10196865T5/de not_active Withdrawn
  • 2001-11-13 US US10/011,700 patent/US6758857B2/en not_active Expired - Fee Related
  • 2001-11-13 US US10/011,494 patent/US6682555B2/en not_active Expired - Fee Related
  • 2001-11-13 JP JP2002558913A patent/JP2004523280A/ja not_active Withdrawn

Patent Citations (4)

Also Published As

Similar Documents

Legal Events